University of Lynchburg adds more Cannabis Studies courses
LYNCHBURG, Va. (WFXR)—The cannabis industry is growing, and the University of Lynchburg's Professional Development Institute is adding programming to accommodate it.
The school first partnered with Green Flower to offer Cannabis Studies a year ago. Now the two are offering nine-week certificate courses online. Max Simon is CEO of Green Flower.
'They're designed to give people the knowledge and skills to enter the three most important job areas in the cannabis industry. Cultivation, manufacturing, and cannabis retail,' said Simon.
Even as the industry grows though, federal reform hasn't been reached and some states like the commonwealth are still putting the breaks on their retail market. In March, Governor Glenn Youngkin vetoed creating a retail marijuana market again, claiming the substance quote 'endangers Virginians' health and safety'.
Simon believes it's only a delay.
'Cannabis legalization is an inevitability,' he said. 'It's not a question of if, it's really a question of when.'
Roanoke College introduces new Cannabis Studies Program
John Zinn is executive director of the Professional Development Institute at the University of Lynchburg.
'With the current state in the commonwealth with cannabis, you know there's a possibility down the road it might open up more and we plan to be ready to meet the market when that happens,' he said about adding more programs.
The new programs are designed to be more accessible for people interested in careers in cannabis. They're shorter, cheaper, and online.
'You don't necessarily have to be in the commonwealth, you can be in markets that are embracing the cannabis industry a little bit more,' he said.
Zinn says enrollment in their cannabis programming has been fairly consistent over the last year, bringing in a couple students every other month to join cohorts of students from all around the country training to join the new industry.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Bill Belichick keeps relitigating his disastrous CBS interview
Bill Belichick is one of the greatest football coaches of all time. His P.R. instincts leave much to be desired. Beyond entrusting his personal brand to his 24-year-old girlfriend, Jordon Hudson, Belichick has a bad habit of not letting sleeping dogs lie and/or dead horses go unbeaten. Case in point, now reports that Belichick's book publicist assured Belichick that the disastrous CBS interview would be only about Belichick's book. Advertisement The report emerged today, more than a month after the CBS interview aired. And it has reanimated a dormant issue. The article cites an April 9 email from Simon & Schuster's senior director of publicity David Kass to Belichick. Wrote Kass: "I can assure you that the conversation [will be] about the book." Kass also reportedly told Belichick the CBS interview would be a "puff piece . . . designed to make everyone look good and sell books." (Somewhat surprisingly, the new report doesn't blame Kass for suggesting that Belichick wear an old football jersey with a giant hole in the neck to the CBS interview.) Per Belichick was "furious" when the CBS interview strayed beyond book topics. Then there's this: "Sources say Belichick had actually shot down several interview opportunities Kass had put in front of him over concerns the media outlets would use his book promotion as a way to pry into subjects not related to the actual book." Advertisement It's a fascinating development, for several reasons. First, the story is smeared with Belichick's (or Hudson's) fingerprints. Which means that one or both decided to dredge up a dead story, weeks after the fact. Which also means that one or both believed the new story would cause people to say, "Well, now we understand why she weirdly refused to let him answer the basic question of how they met." Second, one or both decided to throw Kass under the bus, both directly and by potentially instigating a stray, conspiracy theory-inducing remark that Kass "once helped Jeff Benedict's Robert Kraft-themed book, The Dynasty, reach the New York Times' bestseller list." Kass is painted as the villain in this, the one who lied to Belichick about what the CBS interview was going to be. Third, Belichick did other interviews in which questions unrelated to the book were asked — after the CBS sit-down. Michael Strahan asked a few personal questions on Good Morning America. Ryan Clark asked questions about Hudson on The Pivot Podcast. (Then again, those questions apparently were scripted to help Belichick undo the CBS-related P.R. damage.) Advertisement Fourth, Belichick and/or Hudson apparently have decided to try to get on their side by spoon-feeding information to the outlet. Given the extent to which had been hammering all things Belichick and Hudson, a subtle quid pro quo that gets to play nice in exchange for current and future information would be a smart move by Belichick. Make no mistake about it. The issue is back on the front burner because Belichick and/or Hudson decided it would be a smart move to point a finger at Kass, weeks after the fact. And it's just the latest time Belichick and/or Hudson have blamed others for their own blunders. He/she/they have blamed CBS for editing the interview to create a "false narrative." He/she/they have blamed North Carolina for not having a sufficient P.R. function in place when he arrived. He/she/they now blame Kass for failing to (wait for it) "do his job" properly. It's always someone else's fault. It's never their fault. And they presumably think people will buy the idea that they're the victims of widespread incompetence and malfeasance.
Yahoo
2 days ago
- Yahoo
HAE Q1 Earnings Call: Revenue Misses Expectations, Margin Expansion and Product Focus Highlighted
Blood products company Haemonetics (NYSE:HAE). fell short of the market's revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $330.6 million. Its non-GAAP EPS of $1.24 per share was 1.6% above analysts' consensus estimates. Is now the time to buy HAE? Find out in our full research report (it's free). Revenue: $330.6 million (3.7% year-on-year decline) Adjusted EPS: $1.24 vs analyst estimates of $1.22 (1.6% beat) Adjusted EPS guidance for the upcoming financial year 2026 is $4.85 at the midpoint, missing analyst estimates by 1.2% Operating Margin: 21.6%, up from 8.7% in the same quarter last year Organic Revenue was flat year on year (10.2% in the same quarter last year) Market Capitalization: $3.35 billion Haemonetics reported first quarter results marked by revenue declines, but management emphasized the impact of its evolving product portfolio and operational changes. CEO Chris Simon attributed performance to strong growth in the Hospital segment, led by technologies such as TEG and VASCADE, and highlighted the successful divestiture of the Whole Blood business. He noted that expanded adoption of next-generation products, particularly in Plasma technology, contributed to margin improvement. Simon also referenced the company's ongoing focus on higher-margin product categories and operational discipline as factors that contributed to the quarter's profitability, stating, 'Our industry-leading NexSys, TEG and VASCADE technologies continue to propel our growth in attractive markets.' Looking forward, Haemonetics' guidance reflects a cautious outlook as the company anticipates ongoing headwinds from portfolio transitions and external market factors. Management expects organic growth to be driven mainly by increased utilization and share gains in Plasma and Hospital technologies, while acknowledging a potential rebound in collection volumes later in the year. CFO James D'Arecca warned that reported revenue is expected to decline due to the completed Whole Blood divestiture and continued impacts from the CSL contract transition, but emphasized that gross margin expansion and disciplined cost management should support profitability. D'Arecca stated, 'We expect adjusted operating margin to improve by 200 to 300 basis points... supported by continued gains in adjusted gross margin.' Management traced the quarter's performance to a mix of product portfolio shifts, margin expansion, and strategic focus on high-growth segments, while also pointing to contract transitions and market-specific headwinds. Hospital segment momentum: Growth was led by Hospital products, including Blood Management Technologies and Interventional Technologies, with double-digit increases in both franchises. The TEG viscoelastic testing platform saw accelerated adoption, particularly with the launch of the HN cartridge, driving new account openings and transitions from older models. Vascular Closure advances: The VASCADE MVP and MVP XL devices in the Interventional Technologies franchise delivered over 25% growth due to new account openings and increased U.S. and Japanese utilization. However, legacy VASCADE products for coronary and peripheral procedures saw slower growth, which management aims to address through focused sales efforts. Plasma technology adoption: Plasma revenue was buoyed by the adoption of next-generation technologies like Persona and Express Plus, resulting in share gains and increased margins. Management highlighted new multi-year agreements with major collectors, which are expected to continue contributing to growth. Portfolio transformation and divestitures: The completed divestiture of the Whole Blood business enabled resource reallocation to higher-growth, higher-margin areas. This shift contributed to the significant improvement in overall operating margins and supported disciplined capital allocation, including share repurchases. Leadership and organizational changes: The promotions of Roy Galvin to Chief Commercial Officer and Frank Chan to Chief Operating Officer were cited as key steps to strengthen commercial execution and operations, particularly in supporting the Hospital business's long-term growth plans. Haemonetics expects near-term revenue to be shaped by portfolio transitions, while focusing on margin gains and product adoption to drive future growth and profitability. Product utilization and share gains: Management anticipates that growth will be led by increased utilization of existing devices, especially in Plasma and Vascular Closure, supported by recent extended contracts with major plasma collectors. New hospital product launches and technology conversions are expected to offset headwinds in legacy product lines. Margin expansion and cost discipline: The company projects further improvement in operating margins through portfolio mix shifts towards higher-margin products and ongoing cost control measures. Approximately $30 million in savings are expected over the next two years through regional alignment and operational efficiencies. External risks and market headwinds: Haemonetics identified tariff exposure, timing of contract transitions, and softness in the Chinese market as areas of uncertainty. While management expects U.S. and European momentum to offset challenges, external factors could impact both revenue progression and profitability in the coming quarters. In the next few quarters, the StockStory team will monitor (1) the pace of technology adoption and utilization in the Plasma and Hospital segments, (2) execution against targeted improvements in Vascular Closure—especially legacy product turnaround efforts, and (3) margin performance as cost savings and portfolio transformation initiatives take hold. Progress on regulatory approvals and new product launches will also be important milestones. Haemonetics currently trades at a forward P/E ratio of 14.2×. Should you double down or take your chips? The answer lies in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
VRANKEN-POMMERY MONOPOLE : Broadcast and availability of the presentation document for the Combined Ordinary and Extraordinary General Meeting of June 5, 2025
Press Release Broadcast and availability of the presentation document for the Combined Ordinary and Extraordinary General Meeting of June 5, 2025 Reims, 4th june 2025 Vranken-Pommery Monopole is pleased to announce that its Combined Ordinary and Extraordinary General Meeting of June 5, 2025 will be held at Domaine Pommery in Reims at 3:00 pm. The Group has set up the following link to enable all its shareholders to follow the live or recorded broadcast of this Annual General Meeting: The Group is also making available to its shareholders the document to be presented at the Annual General Meeting on its website at the following address: About Vranken-Pommery Monopole Vranken-Pommery Monopole is a leading wine player in Europe and the second largest champagne group manages 2,600 hectares of land, owned outright or under lease and spread over four vineyards in Champagne, Provence, Camargue and Douro. The group's activities include wine-growing, wine-making, distribution and marketing, with a strong commitment to the promotion of terroirs, sustainable wine-growing and environmental brand portfolio includes: the Vranken, Pommery & Greno, Heidsieck & Co Monopole, Charles Lafitte and Bissinger & Co champagnes; the Rozès and Sao Pédro port wines and the Terras do Grifo Douro wines; the Domaine Royal de Jarras and Pink Flamingo Camargue wines the Château La Gordonne, and Chappelle Gordonne Provence wines; the Louis Pommery California, Louis Pommery England and Brut de France sparkling wines. Vranken-Pommery Monopole is listed on NYSE Euronext Paris ("VRAP") and Brussels ("VRAB"). ISIN: FR0000062796. Contacts Vranken-Pommery Monopole :Franck Delval, Directeur des Contrôles Financiers+33 3 26 61 62 34, comfi@ PresseLaurent Poinsot, +33 1 53 70 74 77, lpoinsot@ Simon, +33 1 53 70 74 65, Attachments Press release VPM 062025 eng Press release VPM 062025 engSign in to access your portfolio
